Having trouble reading this email? View the web version here \| Forward this email to a colleague

Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment versus generic Clopidogrel

AstraZeneca has announced new health economics data from a substudy of the PLATO trial showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with BRILIQUE (ticagrelor) was more cost-effective than treatment with generic clopidogrel...

Read the full story >>

Pharmaceutical & life science news:

		FDA licenses Sanofi Pasteur’s new influenza vaccine delivered by intradermal microinjection Sanofi Pasteur has announced today the FDA has approved the company's supplemental biologics license application (sBLA) for licensure of Fluzone Intradermal (Influenza Virus Vaccine)...

		Twelfth milestone payment as part of its discovery alliance with Boehringer Ingelheim received Evotec AG has announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million...

		Alkermes to merge with Elan Drug Technologies to create Alkermes plc Alkermes will merge with EDT in a cash and stock transaction currently valued at approximately $960 million...

		Biogen Idec and Swedish Orphan Biovitrum receive opinion from EMA Biogen Idec and Swedish Orphan Biovitrum have announced that the European Medicines Agency’s Pediatric Committee has adopted an opinion agreeing to the pediatric investigational plan for the companies’ long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc)...

		Pfizer’s Prevnar 13® meets all study endpoints in two pivotal phase 3 trials in adults aged 50 and older Pfizer Inc. has announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* in adults aged 50 years and older met all study endpoints...

		Merck announces Hope Against Hepatitis C initiative to support fight against Hepatitis C Virus Merck has announced the launch of Hope Against Hepatitis C, an initiative to increase awareness, prevention and diagnosis of hepatitis C virus (HCV) infection...

		Cephalon presents positive results with NUVIGIL in largest shift work disorder trial ever conducted Cephalon, Inc. has presented positive results from a phase IV trial of nearly 400 people with excessive sleepiness associated with shift work disorder...

		Abbott receives FDA approval to expand use of the RX ACCULINK® Carotid Stent System The FDA has approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery)...

		Novartis gains FDA approval for Afinitor® The FDA has approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET)...

		The European Commission approves Pfizer’s Revatio® (sildenafil) the European Commission has approved Revatio® (sildenafil citrate) for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension...

		Sanofi-aventis and Medicines for Malaria Venture join forces to develop innovative malaria drugs Sanofi-aventis and Medicines for Malaria Venture (MMV) have signed an alliance agreement to research malaria treatments as well as the first research project agreement within the framework of the alliance...

Conferences, events & exhibitions:

The Future for UK Pharmaceuticals R&D – Innovation through Partnership
12 May 2011 London, UK

Free webinar: Justifying new technology investments in the Micro QC Lab
Tuesday, May 17, 2011, 3:00pm BST
According to various research studies of pharmaceutical quality control professionals, nearly half of micro QC organisations continue to operate using manual processes. During this free webinar, learn from industry experts how to justify an investment in new technology. During this webinar, you will learn the benefits to automating Micro QC processes, the technologies available, the steps to build a business case, and areas of value to include.

QbD for Pharma
24 - 25 May 2011 Berlin, Germany

10th Annual Congress Recombinant Antibodies
24 - 26 May 2011 Barcelona, Spain

Partnering with Central Labs, ECG and Imaging Labs
25 - 26 May 2011 Brussels, Belgium

Pharma Manufacturing Summit 2011
7 - 9 June 2011 Montreux, Switzerland
The NGP Manufacturing Summit will serve as an arena for senior level executives to engage in a clear and focused dialogue with their peers to procure and examine their business and manufacturing objectives in real time. GDS has elected more than 50 of the most well respected executives in the European pharmaceutical industry. The delegation gathers together to spend two days with their peers to network and share knowledge while assessing new technologies available in the marketplace.

12th Annual Drug Discovery Leaders Summit 2011
8 - 9 June 2011 Le Montreux Palace, Montreux, Switzerland

European Lab Automation Congress 2011
30 June - 1 July 2011 Hamburg, Germany

Free webinar: Justifying new technology investments in the Micro QC Lab

Date: Tuesday, May 17, 2011
Time: 3pm BST
Length: One hour

According to various research studies of pharmaceutical quality control professionals, nearly half of micro QC organizations continue to operate using manual processes. Time consuming, manual tasks result in slower throughput of samples and longer quarantine times, placing a burden on the Micro QC department who must perform low value, manual tasks.

New technologies have become available to create a more efficient and effective Micro QC Lab, but companies have been slow to adopt. Concerns on how to create a business case for the new technology create one stumbling block. During this free webinar, learn from industry experts the steps to justify an investment in new technology.

During this webinar, you will learn:

Benefits to automating Micro QC processes
Technologies available
Steps to build a business case
Areas of value to include

Join European Pharmaceutical Review on LinkedIn

Follow European Pharmaceutical Review on Twitter